drugset / Trial / NCT03452527
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
Timeline
- Start
- 2018-03-26
- Primary completion
- 2019-04-25
- Completion
- 2019-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICON-1 | Unknown | 0.6 mg | Intravitreal |
| Background | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |